N-(3-(1,1-difluoroethyl)-4-phenoxyphenyl)-5-fluoro-4-(pyridin-3-yl)thiazol-2-amine | 1088695-75-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-(1,1-difluoroethyl)-4-phenoxyphenyl)-5-fluoro-4-(pyridin-3-yl)thiazol-2-amine
• 英文别名: N-[3-(1,1-difluoroethyl)-4-phenoxyphenyl]-5-fluoro-4-pyridin-3-yl-1,3-thiazol-2-amine
• CAS: 1088695-75-3
• 化学式: C₂₂H₁₆F₃N₃OS
• 分子量: 427.45
• InChiKey: OZBXCIKQHLAXHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  75.3
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
  申请人：Abbott Laboratories

  公开号：EP2017265A1

  公开（公告）日：2009-01-21

  The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt thereof (in which X1 - X5, R5 - R8b, Z1 - Z2 and Ar1 are defined herein), pharmaceutical compositions including those compounds and a process for making those compounds. The compounds of formula (I) are useful for treating pain, bladder overreactivity, urinary incontinence, inflammatory hyperalgesia by inhibiting the VR1 receptor in mammals.

  本发明公开了通式（I）的新型化合物或其药学上可接受的盐（其中 X1 - X5、R5 - R8b、Z1 - Z2 和 Ar1 在此定义）、包括这些化合物的药物组合物以及制造这些化合物的工艺。式（I）化合物通过抑制哺乳动物体内的 VR1 受体，可用于治疗疼痛、膀胱过度反应、尿失禁、炎性痛觉减退。
• HETEROARYL SUBSTITUTED THIAZOLES AND THEIR USE AS ANTIVIRAL AGENTS.
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：EP2164846A2

  公开（公告）日：2010-03-24
• HETEROARYL SUBSTITUTED THIAZOLES
  申请人：Wang Xiangzhu

  公开号：US20090041720A1

  公开（公告）日：2009-02-12

  The invention provides heteroaryl substituted thiazolo compounds of Formula I and II and pharmaceutically acceptable salts thereof. The variables A and R 3 to R 7 are defined herein. The invention also includes methods for preparing compounds and salts of Formula I and II. The present invention also includes pharmaceutical compositions containing heteroaryl substituted thiazolo compounds and methods for using heteroaryl substituted thiazolo compounds, including methods for using the compounds in the treatment of hepatitis C virus.
• US8183263B2
  申请人：——

  公开号：US8183263B2

  公开（公告）日：2012-05-22
• [EN] HETEROARYL SUBSTITUTED THIAZOLES<br/>[FR] THIAZOLES À SUBSTITUTION HÉTÉROARYLE
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2008147557A2

  公开（公告）日：2008-12-04

  [EN] The invention provides heteroaryl substituted thiazolo compounds of Formula I and II and pharmaceutically acceptable salts thereof. The variables A and R3 to R7 are defined herein. The invention also includes methods for preparing compounds and salts of Formula I and II. The present invention also includes pharmaceutical compositions containing heteroaryl substituted thiazolo compounds and methods for using heteroaryl substituted thiazolo compounds, including methods for using the compounds in the treatment of hepatitis C virus.
  [FR] La présente invention concerne des composés thiazoles à substitution hétéroaryle de formule I et II, ainsi que leurs sels dérivés pharmaceutiquement acceptables. Les variables A et R3 à R7sont définies ci-après. L'invention porte aussi sur des procédés de préparation des composés et des sels de formule I et II. En outre, la présente invention a trait à des compositions pharmaceutiques renfermant des composés de thiazole à substitution hétéroaryle, ainsi qu'à des procédés d'utilisation des composés de thiazole à substitution hétéroaryle, notamment des procédés d'utilisation de ces composés pour le traitement du virus de l'hépatite C.